A randomized, double-blind, placebo-controlled, multicenter, crossover study of the safety, efficacy and pharmacokinetics of two escalating, oral doses of V3381 [indantadol] (200 mg bid and 400 mg bid) for 28 days in patients with diabetic peripheral neuropathic pain (DPNP)
Latest Information Update: 14 Jun 2007
At a glance
- Drugs Indantadol (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Vernalis
- 04 Nov 2006 New trial record.